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Background. Low lean mass is potentially clinically important in older persons, but criteria have not been empirically 
validated. As part of the FNIH (Foundation for the National Institutes of Health) Sarcopenia Project, this analysis sought 
to identify cutpoints in lean mass by dual-energy x-ray absorptiometry that discriminate the presence or absence of weak-
ness (defined in a previous report in the series as grip strength <26 kg in men and <16 kg in women).
Methods. In pooled cross-sectional data stratified by sex (7,582 men and 3,688 women), classification and regression 
tree (CART) analysis was used to derive cutpoints for appendicular lean body mass (ALM) that best discriminated the 
presence or absence of weakness. Mixed-effects logistic regression was used to quantify the strength of the association 
between lean mass category and weakness.
Results. In primary analyses, CART models identified cutpoints for low lean mass (ALM <19.75 kg in men and 
<15.02 kg in women). Sensitivity analyses using ALM divided by body mass index (BMI: ALM
BMI
) identified a second-
ary definition (ALM
BMI
 <0.789 in men and ALM
BMI
 <0.512 in women). As expected, after accounting for study and age, 
low lean mass (compared with higher lean mass) was associated with weakness by both the primary (men, odds ratio 
[OR]: 6.9 [95% CI: 5.4, 8.9]; women, OR: 3.6 [95% CI: 2.9, 4.3]) and secondary definitions (men, OR: 4.3 [95% CI: 3.4, 
5.5]; women, OR: 2.2 [95% CI: 1.8, 2.8]).
Conclusions. ALM cutpoints derived from a large, diverse sample of older adults identified lean mass thresholds 
below which older adults had a higher likelihood of weakness.
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EARLY efforts to create an operational definition of sar-copenia (including the creation of cutpoints) have relied 
on distributional definitions of lean mass (1), with sarcopenia 
defined as a value of appendicular lean mass (ALM)/height2 
(derived from whole-body dual-energy x-ray absorptiometry 
[DXA]) below the young adult mean level of lean mass or was 
based on definitions that further account for body size or fat-
ness (2–4). More recent efforts have added functional and/or 
strength measures to lean mass to define sarcopenia (5,6), but 
no approaches thus far have proposed and validated cutpoints 
and definitions based on discriminative and predictive ability 
using a data-driven approach from a variety of cohort studies.
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The overarching goal of this set of concurrent reports 
from the Foundation for the National Institutes of Health 
(FNIH) Sarcopenia Project was to determine preliminary 
data-driven criteria for clinically relevant weakness and low 
lean mass. The conceptual framework was based on a clini-
cian making a “differential diagnosis” of mobility impair-
ment, defined as slow gait speed. The clinician understands 
that there are many causes of slow walking, one of which 
is weakness. Similarly, low lean mass may be considered a 
potential contributing factor to the development of weak-
ness (7). Data from multiple large cohort studies of aging 
were pooled for this effort (7). The first stage of analyses 
identified sex-specific cutpoints for weakness that discrimi-
nated slow participants (walking speed <0.8 m/s) from 
those who walked faster (8). In the second stage of the anal-
yses, reported herein, we aimed to identify cutpoints in lean 
mass that discriminated those who were weak (grip strength 
<16 kg in women or <26 kg in men) from those who were 
stronger. The findings from this work were used to address 
subsequent goals of the Project, so it is important to con-
sider these results within the context of all other articles in 
this series.
Methods
Participants
The cohort studies and the clinic visit used in this phase 
of the FNIH Sarcopenia Project analysis included: the 
Study of Osteoporotic Fractures (SOF), both the original 
cohort (study Visit 6) (9) and African American cohort 
(study Visit 1) (10); the Osteoporotic Fractures in Men 
Study (MrOS, baseline visit) (11); the Health, Aging and 
Body Composition Study (Health ABC, Year 6 Clinic 
Visit) (12); the Framingham Study Offspring Cohort 
(exam cycles 6 and 7, 1996–2001) (13) and Framingham 
Original cohort (exam cycle 22, 1992–1993) (14); the 
Boston Puerto Rican Health Study (BPRHS, baseline 
visit) (15); Rancho Bernardo (study Visit 7) (16); and 
several smaller clinical trials led by Dr. Anne Kenny at 
University of Connecticut (randomization visit for all 
studies) (17–22). To be included in these analyses, par-
ticipants must have completed, at the time point identi-
fied above, the following measures: objectively measured 
height and weight; body mass index (BMI); ALM (sum of 
lean mass in the arms and legs), leg lean mass (LLM), and 
total fat by DXA; and grip strength. Of the 26,625 par-
ticipants aged 65 years and older in the FNIH Consortium 
pooled data, 7,069 were ineligible because they were in 
studies that did not have DXA scans; 6,364 were not eli-
gible for DXA scans within their study; 1,170 were eli-
gible but missing DXA data; and an additional 752 were 
missing data for other covariates, yielding a final sample 
size of 11,270 (7,582 men and 3,688 women). Participants 
excluded due to missing data were older, slower, weaker, 
had lower BMI, and were more likely to be women than 
those included in the analyses.
Assessment of Lean Mass
ALM, LLM, and total body fat (TBF) were assessed 
using DXA, on Hologic 4500 machines in MrOS, Rancho 
Bernardo, and Health ABC; on Hologic 2000 machines in 
SOF (both the original and African American cohorts); and 
Lunar Prodigy machines in Framingham (both the Original 
and Offspring cohorts), BPRHS, and the clinical trials at the 
University of Connecticut.
Assessment of Grip Strength and the Definition of 
weakness
Maximum grip strength of either hand was meas-
ured by handheld dynamometers. In the first phase of 
analyses (reported in an accompanying article) (8), the 
cutpoint for grip strength as a discriminator of slow-
ness (defined as a walking speed of ≤0.8 m/s) was iden-
tified using classification and regression tree (CART) 
analysis (23). Men with a grip strength less than 26 kg 
and women with a grip strength less than 16 kg were 
defined as “weak.” A secondary cutpoint for weakness 
based on grip strength standardized to body size (ie, the 
ratio of grip strength to BMI, weakness
BMI
) was identi-
fied for men (men with a ratio <1.0 defined as weak) 
and women (women with a ratio of <0.56 defined as 
weak.) Those analyses to identify a cutpoint in grip 
strength included 20,847 participants, of whom 10,036 
were also included in our analyses; 1,207 participants 
were included our analyses but not included in the grip 
strength analyses. Most of the exclusions from the grip 
strength analyses were due to missing data for walk-
ing speed; and most of the exclusions from the present 
analyses were due to missing values for body composi-
tion (ALM or body fat).
Statistical Analysis
LOESS plots were used to describe the overall shape 
of the relationship between lean mass (both ALM and 
ALM
BMI
) with grip strength and walking speed; Pearson 
correlation coefficients were calculated.
CART analysis was then performed to derive clinically 
meaningful cutpoints for lean mass as a discriminator of 
weakness. CART is particularly advantageous to this study 
because (i) the relationship between candidate predictors 
and weakness does not require specification, (ii) CART can 
identify complex multiway interactions between potentially 
important variables (eg, BMI, height), and (iii) predictors 
and cutpoints are selected to optimize discrimination of the 
outcome (weakness).
CART analysis was performed using the rpart proce-
dure of R software (version 2.10.1), and cross-validation 
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was used to “prune” less important splits to prevent 
overfitting and produce a more parsimonious tree. 
Cross-validation was performed by randomly parti-
tioning the pooled data into 10 equally sized mutually 
exclusive data sets (ie, each set excluded 10% of the 
original pooled data). The tree was then applied to 10 
subsamples that contained 90% of the data (ie, 10% 
of the data was left out of each subsample), and the 
prediction error from each subsample was calculated. 
The 10 prediction errors (error sum of squares) were 
used to calculate the empirical standard error of the 
prediction error. Following published guidelines (24), 
the tree was pruned to the most parsimonious tree that 
was within 1 SE of the tree with the smallest prediction 
error. This pruned tree contains the final set of lean 
mass cutpoints.
Several CART models were run. First, ALM and LLM 
were entered into a CART model as the only potential dis-
criminators of weakness (defined as grip strength <26 kg 
for men and <16 kg for women). Then, body size variables 
(height, weight, BMI, TBF) were added to the model. 
Third, measures of lean mass standardized to body size (the 
ratio of ALM to each measure of body size) were added 
and included ALM
height
, ALM
weight
, ALM
height2
, ALM
BMI
, 
ALM
TBF
, LLM
height
, LLM
weight
, LLM
height2
, LLM
BMI
, and 
LLM
TBF
. Finally, we consider only ALM
BMI
 and ALM as 
potential discriminators of weakness.
We report the prevalence for low lean mass by various 
subgroups in the cohorts (such as age, BMI, and history 
of disease) and the likelihood of prevalent weakness by 
low lean mass across these subgroups. We also report the 
likelihood of slowness and inability to rise from a chair by 
various weakness and low lean mass categories. These esti-
mates were derived using mixed-effects logistic regression 
that included a random effect for cohort to account for the 
heterogeneity between studies.
Results
ALM was positively correlated with grip strength in men 
(r = .47, p < .001) and somewhat less strongly in women  
(r = .33, p < .001) (Figure 1). ALM was only modestly posi-
tively correlated with walking speed in men (r = .11, p < 
.001) and was inversely correlated with walking speed in 
women (r = −.20, p < .001). ALM
BMI
 was positively cor-
related with grip strength (r = .42, p = <.001) and walking 
speed (r = .24, p < .001) in men as well as in women (grip 
strength, r = .22, p < .001 and walking speed, r = .07, p < 
.001). Body weight was strongly correlated with ALM in 
both men (r = .80, p < .001) and women (r = .81, p < .001).
The CART models for the primary definition of weak-
ness (grip strength <16 kg in women and <26 kg in men) 
demonstrated that ALM was the best discriminator of weak-
ness, regardless of inclusion of body size variables (weight, 
TBF, height, height2 or BMI) or lean mass variables stand-
ardized to body size, or both. (Figure 2).
In men, a single cutpoint for ALM was found. Men with 
an ALM less than 19.75 kg were defined as having low lean 
mass; the prevalence of weakness was 18.3% in this group 
compared with only 2.5% for men with higher lean mass 
(ALM ≥ 19.75 kg).
In women, two cutpoints for ALM were found: one at 
15.02  kg and another at 12.09 kg. For parsimony, and to 
propose a definition analogous to that for men, we defined 
two groups of women: those with low lean mass (ALM 
< 15.02 kg) and higher lean mass (ALM ≥ 15.02 kg). The 
prevalence of weakness for women with low lean mass was 
29.8% compared with a prevalence of weakness of 11.0% 
for women with higher lean mass.
In secondary analyses, for men, when ALM
BMI
 and BMI 
were the only potential discriminators of weakness, one 
cutpoint in ALM
BMI
 was found. In these secondary analy-
ses, we defined men with low lean mass as having a value 
of ALM
BMI 
less than 0.789 (prevalence of weakness was 
Figure 1. Scatterplots and correlation of appendicular lean mass (ALM) or ALM/body mass index (BMI) versus grip strength or walking speed for men and 
women in the FNIH (Foundation for the National Institutes of Health) Sarcopenia Project.
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11.8%); men with an ALM
BMI
 more than or equal to 0.789 
had higher lean mass and a prevalence of weakness of 2.4% 
(Figure 3).
In secondary analyses, for women, when ALM
BMI
 and 
BMI were the only potential discriminators of weakness 
included in the CART model, one cutpoint in ALM
BMI
 was 
found: 0.512 (Figure 3), and for those with ALM
BMI
 more 
than or equal to 0.512, a second cutpoint was found for BMI 
(23.7 kg/m2). In the secondary analyses, we defined women 
with low lean mass as having ALM
BMI
 less than 0.512 (prev-
alence of weakness was 31.0%); women with ALM
BMI
 more 
than or equal to 0.512 had a prevalence of weakness 16.8% 
(Figure 3). Of the women with ALM
BMI
 more than or equal 
to 0.512, those who had a BMI less than 23.7 kg/m2 had 
a prevalence of weakness of 12.0%, whereas those with a 
BMI of more than or equal to 23.7 kg/m2 had a prevalence 
of weakness of 24.2%.
Men with low lean mass were more likely to be weak 
compared with those with higher lean mass, after account-
ing for age and study by both the primary definition (odds 
ratio [OR]: 6.9 [95% CI: 5.4, 8.9]) or secondary definition 
(OR: 4.3 [95% CI: 3.4, 5.5]) (Table 1). Similarly, women 
with low lean mass were also more likely to be weak com-
pared with those with higher lean mass by the primary defi-
nition (OR: 3.6 [95% CI: 2.9, 4.3]) or secondary definition 
(OR: 2.2 [1.8, 2.8]), although the strength of the association 
was smaller in magnitude than it was for men. For most 
stratified analyses, the association between low lean mass 
and weakness was significant (p < .05), while the point esti-
mates varied by strata (although the interaction by stratify-
ing factors was not significant for any model).
In men, when weakness and low lean mass were con-
sidered jointly in the same model with slowness as the 
outcome, both factors were independently associated with 
prevalence of slowness (Table  2). Men who were weak 
(either by grip strength alone or by grip strength standard-
ized to BMI) were about 3- to 4.5-fold more likely to be 
slow and 2.5- to 3.0-fold more likely to be unable to rise 
from a chair than men who were not weak. Men with low 
lean mass (either by ALM or ALM
BMI
) were about twice as 
likely to be slow compared with men with higher lean mass. 
Men with low lean mass by ALM, but not ALMBMI, were 
about 1.3- to 1.6-fold more likely to be unable to rise from 
a chair than men with higher lean mass.
In women, when weakness and low lean mass were 
considered jointly in the same model with slowness as the 
outcome, only weakness was consistently associated with 
slowness. Women who were weak (either by grip strength 
lone or by grip strength standardized to BMI) were 2- to 
3-fold more likely to be slow than women who were not 
weak. One the other hand, and in contrast to results for 
men, women with low lean mass based on ALM had a 
somewhat lower likelihood of being slow or unable to rise 
from a chair compared with women with higher lean mass. 
Women with low lean mass (based on ALM
BMI
) had about a 
50% increased likelihood of slowness after adjustment for 
Figure 2. Classification and regression tree models for measures of lean mass, body size, and lean mass standardized to body size discriminating weakness in 
older men and women in the FNIH (Foundation for the National Institutes of Health) Sarcopenia Project. Model included the following potential discriminators of 
weakness (grip strength <16 kg in women and <26 kg in men): ALM (appendicular lean mass), height, weight, height2, total body fat (TBF), BMI (body mass index), 
ALM
height
 (ALM/height), ALM
weight
 (ALM/weight), ALM
height2
 (ALM/height2), ALM
BMI
 (ALM/BMI), ALM
TBF
 (ALM/TBF), LLM
height
 (LLM/height; LLM = leg lean 
mass), LLM
weight
 (LLM/weight), LLM
height2
 (LLM/height2), LLM
TBF
 (LLM/TBF), and ALM
BMI
 (LLM/BMI).
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weakness based on grip strength alone. However, when the 
association between ALM
BMI
 and slowness was adjusted 
for weakness standardized to BMI, the association was not 
significant. ALM
BMI
 was not significantly associated with 
inability to rise from a chair for women.
When we compare the prevalence of low lean mass by 
our definition based on ALM with the prevalence of low 
lean mass by Baumgartner, overall percent agreement was 
83.0% for men and 75.4% in women (Table 3). When we 
compare the prevalence of low lean mass by our definition 
based on ALM
BMI
 with the prevalence of low lean mass by 
Baumgartner, the overall percent agreement is 69.1% in 
men and 70.7% in women.
Discussion
The goal of these analyses, using pooled data from sev-
eral large cohort studies of older men and women, was to 
identity cutpoints in values of low lean mass that discrimi-
nated those who were weak from those who were not weak. 
Primary analyses resulted in a definition of low lean mass 
as ALM less than 19.75 kg in men and less than 15.02 kg in 
women. Sensitivity analyses suggested an alternative defini-
tion using a value of ALM standardized to BMI (ALM
BMI
). 
Men with a value of ALM
BMI 
less than 0.789 and women 
with a value of ALM
BMI
 less than 0.512 were considered to 
have low lean mass by this secondary definition.
While our analyses were not designed to define or 
evaluate “sarcopenic obesity,” our results suggest that 
body size and potentially fatness influence the association 
between lean mass and weakness. This finding is similar 
to another report (4) that found that low lean mass based 
on the Baumgartner (1) criteria using ALM/height2 was 
less strongly related to physical disability than a measure 
of low lean mass that was adjusted for height and body fat 
mass (2). On the other hand, measures of obesity were not 
selected by the CART models as primary discriminators of 
weakness in older people.
The associations between our definitions of low lean 
mass and concurrent weakness are quite strong as would be 
expected by our analytical methodology. Men who had low 
lean mass by the primary definition based on ALM alone 
were about 7 times more likely to be weak (grip strength 
<26 kg) than men with higher lean mass. In women, the 
association between low lean mass and weakness was some-
what lower but still substantial, as women with low lean 
mass by the primary definition based on ALM alone were 
about 4 times more likely to be weak (grip strength <16 kg) 
than women with higher lean mass. However, the analysis 
technique employed requires caution when interpreting 
these data. The strong associations between our proposed 
definitions of low lean mass and weakness are not surpris-
ing, because of the analysis method (CART) derived the 
cutpoints to maximize the association between lean mass 
and weakness. We expressed the association between our 
lean mass cutpoints and weakness as ORs to further ease 
the clinical interpretation of our results. To understand the 
clinical implications of the proposed definitions of low lean 
mass described here, further analyses must be completed, 
including those of longitudinal data that would establish 
the predictive validity of our cutpoints and the independ-
ent association of these cutpoints with clinical outcomes 
thought to be related to weakness and low lean mass.
The association between low lean mass and slowness was 
independent of weakness in men. Men who had low lean 
mass (by either definition) were about 2–4.5 times more 
likely to be slow when compared with men with higher 
lean mass after accounting for weakness. On the other 
hand, in women, the association between low lean mass and 
Figure 3. Classification and regression tree models for ALM
BMI
 and BMI discriminating weakness in older men and women in the FNIH (Foundation for the 
National Institutes of Health) Sarcopenia Project. Model included ALM and ALM
BMI
 (ALM/BMI) as potential discriminators of weakness (grip strength <16 kg in 
women and <26 kg in men). ALM = appendicular lean mass; BMI = body mass index.
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Table 1. Prevalence of Low Lean Mass (based on ALM or ALM
BMI
) and Likelihood of Weakness Across Various  
Subsamples in the FNIH Sarcopenia Project*
N
Prevalence of 
Weakness
OR (95% CI) for Weakness
Low Lean Mass 
(based on ALM)
Low Lean Mass  
(based on ALM
BMI
)
Men
 Overall 7,582 0.04 6.9 (5.4, 8.9) 4.3 (3.4, 5.5)
 Age
  65–79 6,001 0.03 6.2 (4.4, 8.8) 3.9 (2.8, 5.5)
  80 1,581 0.11 5.0 (3.5, 7.2) 3.3 (2.4, 4.7)
 BMI
  Normal weight/underweight 2,198 0.07 6.2 (4.2, 9.1) 7.5 (5.0, 11.1)
  Overweight 3,848 0.04 8.6 (5.8, 12.8) 5.3 (3.7, 7.7)
  Obese 1,536 0.03 10.3 (3, 35.7) 4.7 (2.3, 9.7)
 Height
  Tertile 1 (<1.7080 m) 2,524 0.09 4.4 (3.2, 6.0) 2.8 (2.0, 3.9)
  Tertile 2 (≥1.708 m, <1.765 m) 2,514 0.03 3.6 (2.1, 6.4) 1.3 (0.7, 2.4)
 Tertile 3 (≥1.7650 m) 2,544 0.01 13.7 (5.0, 37.7) 5.6 (2, 15.9)
 Cancer
  Yes 1,791 0.03 6.8 (3.8, 12.1) 5.8 (3.3, 10.2)
  No 5,578 0.05 7.8 (5.9, 10.4) 4.4 (3.3, 5.7)
 CHF
  Yes 373 0.10 9.2 (4.2, 19.8) 4.7 (2.2, 10.0)
  No 6,248 0.04 7.6 (5.6, 10.3) 4.7 (3.5, 6.2)
 COPD
  Yes 625 0.04 5.2 (2.2, 12.4) 7.0 (2.8, 17.6)
  No 5,357 0.03 8.9 (6.2, 12.8) 4.5 (3.2, 6.3)
 Diabetes
  Yes 759 0.07 5.1 (2.4, 10.8) 2.7 (1.4, 5.1)
  No 6,809 0.04 7.3 (5.6, 9.5) 4.5 (3.5, 5.9)
Women
 Overall 3,688 0.19 3.6 (2.9, 4.3) 2.2 (1.8, 2.8)
 Age
  65–79 2,633 0.15 3.5 (2.7, 4.5) 2.4 (1.8, 3.1)
  80 1,055 0.29 2.9 (2.1, 4.0) 2.0 (1.4, 2.9)
 BMI
  Normal weight 1,455 0.24 4.3 (3.0, 6.2) 2.9 (1.8, 4.7)
  Overweight 1,299 0.17 3.2 (2.3, 4.5) 3.0 (2.1, 4.3)
  Obese 934 0.14 3.6 (2.0.1, 6) 3.3 (2.2, 5.1)
 Height
 Tertile 1 (<1.560 m) 1,229 0.28 3.3 (2.3, 4.6) 1.3 (1.0, 1.8)
 Tertile 2 (≥1.560 m, <1.610 m) 1,225 0.18 2.4 (1.7, 3.5) 1.8 (1.1, 2.8)
 Tertile 3 (>1.610 m) 1,234 0.11 2.5 (1.7, 3.8) 2.4 (1.0, 5.7)
 Cancer
  Yes 241 0.26 5.3 (2.7, 10.6) 1.8 (0.8, 3.9)
  No 2,508 0.17 3.8 (2.9, 5) 2.4 (1.8, 3.1)
 CHF
  Yes 136 0.26 6.3 (2.7, 14.6) 1.7 (0.7, 4.3)
  No 2,481 0.23 3.4 (2.7, 4.2) 2.2 (1.7, 2.8)
 COPD
  Yes 196 0.20 5.6 (2.6, 12.2) 2.5 (1.1, 5.9)
  No 1,356 0.22 3.5 (2.6, 4.6) 2.5 (1.7, 3.6)
 Diabetes
  Yes 277 0.21 2.5 (1.2, 4.9) 1.3 (0.6, 2.9)
  No 3,313 0.19 3.7 (3, 4.5) 2.3 (1.9, 2.9)
Notes: ALM  =  appendicular lean mass; BMI  =  body mass index; CHF  =  congestive heart failure; COPD  =  chronic obstructive pulmonary disease; 
FNIH = Foundation for the National Institutes of Health; OR = odds ratio.
*Weakness defined as grip strength <26 kg in men and <16 kg in women; low lean mass based on ALM defined as <19.75 in men and <15.02 in women; low lean 
mass based on ALMBMI defined as <0.789 in men and <0.512 in women. Medical conditions based on self-report of physician diagnosis. A total of 213 men and 939 
women missing cancer information, 961 men and 1,071 women missing CHF information, 1,600 men and 2,136 women missing COPD information, and 14 men and 
98 women missing diabetes status. No significant interactions were found in the stratified analyses.
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slowness was inconsistent across definitions and was not 
consistently independent of concurrent weakness. These 
sex differences could be due to a number of factors. Men 
and women have drastically different body types and body 
composition, and women have more disability than men. 
It is possible that the association between body size, lean 
mass, weakness, and slowness truly differs between men 
and women. Another possibility is that differences between 
single-sex cohorts in the pooled data set (such as SOF and 
MrOS, for example) explain the discrepant results.
Our results are not directly comparable to other proposed 
definitions of low lean mass or sarcopenia, because these 
other definitions have accounted for body size in a different 
manner than our analyses. For example, the Baumgartner 
definition (1) (which has been included in consensus state-
ments about sarcopenia) divides ALM by height2 to quan-
tify lean mass and then defines individuals as “sarcopenic” 
if their value is at least 2 SDs below a young normal mean 
value. This equates to 7.26 kg/m2 for men and 5.45 kg/
m2 for women. We found modest agreement between our 
definitions and the Baumgartner definition of low lean 
mass; thus, we conclude that our cutpoints and other sarco-
penia definitions, as discussed in an accompanying report 
from this project (25), differentially classify individuals. 
We could not compare our definition against others that 
used non-DXA methods to determine lean mass (such as 
bioelectrical impedance analysis [BIA]) (3), because BIA 
was not available in most participating cohorts.
There are some limitations of these analyses. First, 
CART, by definition, partitions data into groups, even 
when the underlying relationship between the predictor 
and outcome is linear. Second, our CART models did not 
account for differences between studies included in the 
model, although we did account for study in subsequent 
logistic models. Third, while we accounted for cohort 
study a random effect in the logistic models, we did not 
specifically correct or adjust values to account for differ-
ences across cohorts. For example, the cohorts used vari-
ous makes and models of DXA machines. There are no 
methods aside from in vivo cross-calibration studies that 
Table 2. Likelihood of Slowness* or Inability to Complete Chair Stands† (OR, 95% CI)‡, by Weakness and low  
Lean Mass in the FNIH Sarcopenia Project§
Men Women
Model 1 Weak Low lean mass (ALM) Weak Low lean mass (ALM)
 Slowness 3.04 (2.11, 4.38) 1.56 (1.16, 2.09) 2.21 (1.72, 2.83) 0.74 (0.59, 0.92)
 Inability to complete chair stands 2.46 (1.62, 3.73) 1.32 (0.94, 1.85) 2.05 (1.37, 3.08) 0.49 (0.36, 0.69)
Model 2 Weak Low lean mass (ALM
BMI
) Weak Low lean mass (ALM
BMI
)
 Slowness 2.91 (2.02, 4.17) 2.12 (1.66, 2.71) 1.96 (1.53, 2.51) 1.55 (1.20, 2.02)
 Inability to complete chair stands 2.35 (1.56, 3.55) 1.60 (1.21, 2.12) 1.62 (1.09, 2.40) 1.26 (0.86, 1.83)
Model 3 Weak
BMI
Low lean mass (ALM) Weak
BMI
Low lean mass (ALM)
 Slowness 4.24 (3.20, 5.62) 1.71 (1.28, 2.28) 2.91 (2.31, 3.66) 0.86 (0.69, 1.07)
 Inability to complete chair stands 2.90 (2.10, 4.01) 1.39 (0.99, 1.94) 2.40 (1.67, 3.46) 0.54 (0.39, 0.75)
Model 4 Weak
BMI
Low lean mass (ALM
BMI
) Weak
BMI
Low lean mass (ALM
BMI
)
 Slowness 3.55 (2.64, 4.79) 1.71 (1.32, 2.22) 2.77 (2.18, 3.51) 1.27 (0.97, 1.66)
 Inability to complete chair stands 2.63 (1.86, 3.70) 1.37 (1.02, 1.84) 2.31 (1.58, 3.39) 1.04 (0.70, 1.55)
Notes: ALM = appendicular lean mass; BMI = body mass index; FNIH = Foundation for the National Institutes of Health; OR = odds ratio.
*Slowness is walking speed ≤0.8 m/s. For men, N = 337 (4.7%); 7,113 men included in slowness models. For women, N = 673 (22.8%); 2,950 women included 
in slowness models.
†Inability to complete five repeated chair stands. For men, N = 250 (3.5%); 7,095 men included in chair stand models (487 men were missing data for chair stands 
ability). For women, N = 198 (6.7%); 2,971 women included in chair stand models (717 women were missing data for chair stands ability).
‡Both weakness and low lean mass included in the same model adjusted for age and study. Slowness models include study as a random effect. Chair stands models 
include study as a covariate since the mixed-effects logistic regression models with study as a random effect did not converge.
§Weak defined as grip strength <26 kg in men and <16 kg in women; Weak BMI defined as grip strength/BMI as <1.001 in men; <0.56 in women; low lean mass 
based on ALM defined as <19.75 kg in men and <15.02 kg in women; low lean mass based on ALM
BMI
 defined as <0.789 in men and <0.512 in women.
Table 3. Cross-Classification of Low Lean Mass by Baumgartner, ALM, and ALM
BMI
*
Baumgartner criterion ALM criterion ALM
BMI
 criterion
Men Low lean mass High lean mass Low lean mass High lean mass
 Low lean mass 5,510 (72.7%) 1,197 (15.8%) 4,657 (61.4%) 1,390 (18.3%)
 High lean mass 97 (1.3%) 778 (10.3%) 950 (12.5%) 585 (7.7%)
Women Low lean mass High lean mass Low lean mass High lean mass
 Low lean mass 2,050 (55.6%) 28 (0.8%) 2,462 (66.8%) 615 (16.7%)
 High lean mass 879 (23.8%) 731 (19.8%) 467 (12.7% 144 (3.9%)
Notes: ALM = appendicular lean mass; BMI = body mass index.
*Low lean mass based on ALM criterion: <19.75 kg in men, <15.02 kg in women. Low lean mass based on ALM
BMI
 criterion: <0.789 in men, <0.512 in women. 
Baumgartner criteria: ALM/height2 = 7.26 kg/m2 in men and 5.45 kg/m2 in women.
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can accurately compare soft tissue estimates across DXA 
machines (26). As the machines included in this project 
were located throughout the world, such a study was not 
feasible. Additionally, unlike T-scores for bone mineral 
density (BMD) in the diagnosis of osteoporosis (which are 
used in part to account for machine differences in BMD 
estimates), there are no population-based values for all the 
DXA manufacturers for all the soft tissue compartments 
that would allow calculation for t or Z scores. Finally, no 
statistical model alone can identify a disease state. Thus, 
further work is necessary to understand the biological 
implications of these results.
We intend for the cutpoints in ALM and ALM
BMI
 to be 
used within the context of the larger analysis project we 
describe in which we are trying to identify those older 
persons who are slow and weak whose impairments are 
likely attributable to lower levels of lean mass. We have 
shown that there is a level of ALM and ALM
BMI
 below 
which strength is lower. In another report in this series, 
the independent predictive validity of these lean mass cut-
points for future mobility impairment is evaluated. Given 
the discordant literature that suggests that lean mass may 
not be independently predictive of functional decline 
once strength is known (27), these next analyses will be 
imperative.
The conceptual framework we used for this larger pro-
ject—that there is a clinical syndrome that includes walking 
speed, strength, and lean mass that identifies individuals at 
risk for disability—is similar to the framework described 
by other consensus groups that have addressed this broad 
topic of “sarcopenia.” However, there is not clear consen-
sus regarding which part or parts of this clinical syndrome 
constitute “sarcopenia” and which should be designated by 
some other distinction such as “mobility impairment with 
clinically relevant weakness and low lean mass.” To avoid 
confusion, we prefer terminology that precisely describes 
the results. For example, we have identified values of low 
lean mass that discriminate weakness in older adults.
In summary, we have identified cutpoints in lean mass 
that discriminate those who are weak from those who are 
stronger; secondary analyses suggest that adjustment for 
body size may influence the cutpoints selected. Different 
values were found in men and women, given the sex differ-
ences in body size. Future analyses must evaluate the inde-
pendent predictive validity of these cutpoints.
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